Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers.
about
Evidence-based hypertension treatment in patients with diabetesMetabolic syndrome and chronic kidney disease in an adult Korean population: results from the Korean National Health Screening.Metabolic syndrome in hypertensive patients: An unholy alliance.Genipin inhibits mitochondrial uncoupling protein 2 expression and ameliorates podocyte injury in diabetic mice.Assessment of vascular function in individuals with hyperglycemia: a cross-sectional study of glucose - induced changes in digital volume pulse.Chronic Kidney Disease in Non-Diabetic Older Adults: Associated Roles of the Metabolic Syndrome, Inflammation, and Insulin Resistance.Diabetes and hypertension: is there a common metabolic pathway?Metabolic syndrome and abdominal fat are associated with inflammation, but not with clinical outcomes, in peritoneal dialysis patients.Obesity-related metabolic syndrome: mechanisms of sympathetic overactivity.Vasodilating versus first-generation β-blockers for cardiovascular protection.Medical management and strategies to prevent coronary artery disease in patients with type 2 diabetes mellitus.Anti-hypertensive drug treatment of patients with and the metabolic syndrome and obesity: a review of evidence, meta-analysis, post hoc and guidelines publications.Obesity-associated sympathetic overactivity in children and adolescents: the role of catecholamine resistance in lipid metabolism.Application of plasma lipidomics in studying the response of patients with essential hypertension to antihypertensive drug therapy.Benefit of Vasodilating β-Blockers in Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention: Nationwide Multicenter Cohort Study.Adipose afferent reflex response to insulin is mediated by melanocortin 4 type receptors in the paraventricular nucleus in insulin resistance rats.Long-Term Anti-Hypertensive Therapy and Stroke Prevention: A Meta-Analysis.Effects of Carvedilol Compared to Nebivolol on Insulin Resistance and Lipid Profile in Patients With Essential Hypertension.
P2860
Q26851738-4D2DF247-6027-4428-9ADA-8EB56BF5E158Q33578508-6308C5E1-5481-4FB2-A20F-B108F9C698F2Q34251860-3F4E3F28-3DEE-42DE-BAB2-CA8C95F18811Q34358426-CF3E436B-C12B-4E7A-8AD0-C74B1E993D0EQ35494290-B5749E0F-8CC9-4935-BA66-E57343FE86A9Q35796995-52061511-E36F-4E6D-A0FA-CE874F31DB56Q35857205-804C1758-926E-4F8E-9475-BA9464A3A39CQ36964554-8DE1E09F-DF02-46A7-ADD4-4CDE3DD01DDBQ37323375-F27A4B6E-0698-4E94-90D9-22492C0515FBQ37995858-D22920BC-065D-439B-AD91-A7FA4DD51969Q38079914-C6270267-DEC6-4E54-BFDE-2FEFFA643CA7Q38444730-BF5439F5-CB50-41F6-8D09-07040D00244FQ38613061-D0C90329-355C-4258-A527-A2AE517E2282Q44696741-7921027A-488A-42BF-88EB-7245DAFD7F26Q47098635-624FE004-8DB6-4572-9E7D-DADDA6CD114CQ48244748-68D34AC0-D3EE-4776-92C6-DB7C7B5E4406Q51017958-EF0C749A-1ECD-4573-A0E0-1B8E6ED3C380Q51285745-FD65DBCD-672C-4F48-95BC-E5B65C3EB281
P2860
Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Hypertension, dyslipidemia, an ...... ts of vasodilating β-blockers.
@en
Hypertension, dyslipidemia, an ...... ts of vasodilating β-blockers.
@nl
type
label
Hypertension, dyslipidemia, an ...... ts of vasodilating β-blockers.
@en
Hypertension, dyslipidemia, an ...... ts of vasodilating β-blockers.
@nl
prefLabel
Hypertension, dyslipidemia, an ...... ts of vasodilating β-blockers.
@en
Hypertension, dyslipidemia, an ...... ts of vasodilating β-blockers.
@nl
P2860
P921
P1476
Hypertension, dyslipidemia, an ...... ts of vasodilating β-blockers.
@en
P2093
Prakash Deedwania
P2860
P356
10.1111/J.1751-7176.2010.00386.X
P577
2010-11-08T00:00:00Z